Charlotte Teunissen, PhD, VU University Medical Center Amsterdam, Amsterdam, The Netherlands, discusses the MIRIADE training program where they will train 15 novel biomarker developers (PhD students) to kick-start the development of dementia biomarkers. This program will allow for the comparison of different development workflows, which means that factors that result in successful biomarker development can be identified and implemented in future projects. Prof. Teunissen discusses how these PhD students have already developed highly successful single immuno-assays for biomarker candidates picked from a large data set. This interview took place at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases hosted in Barcelona, Spain.